Abstract: 

The invention herein disclosed relates to a novel biomarker for the assessment of bladder outlet obstruction (BOO) in urine samples of male patients with lower urinary tract symptoms. Hence, the urinary concentration of ATP is presented as a biomarker of bladder outlet obstruction, enabling the development of a commercial diagnostic kit to be used in general practice.

Background: 

The present application discloses ATP as a biomarker of bladder outlet obstruction (BOO) in patients with benign prostatic hyperplasia (BPH), allowing an effective and non-invasive diagnosis of BOO. Accessing BOO is essential when evaluating male patients with lower urinary tract symptoms. Until now, there is no accessible, reliable and non-invasive test of BOO. The inventors of the current application analysed urine samples from patients with BOO and from normal controls and found that ATP concentration is significantly higher in obstructed patients. This biomarker used in a portable device has a substantial power to discriminate between obstructed and non-obstructed individuals.

Benefits: 

- First tested urinary marker of bladder outlet obstruction;
- Potential for application in a portable device to identify the ATP concentration in urine that will allow to:

1) Determine the concentration of this biomarker (BMK) in urine sample, adjusted to the voided volume;
2) Compare the subject urinary level to a predetermined reference value.

Advantages over current existing technologies for evaluation of BOO (uroflowmetry and pressure/flow studies) are shown on Table 1.

Potential comercial use/applications: 

Non-invasive molecular diagnostic/screening devices